Vidac Pharma is happy to inform that it received an official Notice of Allowance from the US Patent Office (USPTO) for its new Patent on a new Chemical synthesis pathway for production of its Drug Candidate VDA1102 presently in Clinical Stage.
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com
London (UK), Rehovot (IL), Nov. 13th, 2023
VDA 1102 is a potent new chemical entity created by the Company against in particular Non-Melanoma Skin Cancer (NMSC) and was proven efficacious in Phase 2 for both advanced Actinic Keratosis and in preliminary clinical results for Cutaneous T-Cell Lymphoma. The Company expects that this new chemical pathway will allow for mass production of the Active Pharmaceutical Ingredient (API) in proprietary and economic terms.
Disclaimer
The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC but is for informational purposes only.
Vidac Pharma Holding PLC
Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
investors@vidacpharma.com
+972-54-4257381
+972 (0)779300647